Stroke drug may work hours later than thought
NCT ID NCT05752916
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a clot-busting drug called rhTNK-tPA can help people having a stroke when given 4.5 to 24 hours after symptoms begin. It included 570 adults with a stroke that did not involve a large blocked artery. The goal was to see if the drug leads to better recovery (less disability) at 90 days compared to standard antiplatelet therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA)
What this could lead to
If it works, this could extend the time window for clot-busting treatment in stroke patients, allowing more people to recover with less disability.
What could go wrong
This is a completed Phase 4 trial, but results are not yet published. The drug may not improve outcomes beyond standard care and carries a risk of bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, China